• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ocugen, Inc. - Common Stock (NQ:OCGN)

    1.045 +0.015 (+1.46%)
    Delayed Quote Updated: 1:32 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,494,457
    Open 1.030
    Bid (Size) 1.040 (24,500)
    Ask (Size) 1.050 (30,300)
    Prev. Close 1.030
    Today's Range 1.010 - 1.050
    52wk Range 0.9700 - 2.725
    Shares Outstanding 257,328,085
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ocugen to Participate in Upcoming Scientific Conferences
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Participate in Upcoming October Investor and Industry Conferences
    From Ocugen
    Via GlobeNewswire

    Performance

    YTD
    -24.3%
    -24.3%
    1 Month
    -21.4%
    -21.4%
    3 Month
    -29.4%
    -29.4%
    6 Month
    -41.6%
    -41.6%
    1 Year
    -35.9%
    -35.9%

    More News

    Read More
    News headline image
    Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances ↗
    Via MarketBeat
    Ocugen (NASDAQ:OCGN) Falls on Mixed Q2 Results as Revenue Beat Offsets Wider Loss ↗
    Via Chartmill
    Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
    Via Chartmill
    News headline image
    Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Participate in Upcoming September Investor and Industry Conferences
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts ↗
    Via MarketBeat
    News headline image
    Ocugen (OCGN) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Retirement
    News headline image
    Ocugen Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Ocugen Provides Business Update with Second Quarter 2026 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Participate in Upcoming August Investor Conferences
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances ↗
    Via MarketBeat
    News headline image
    Ocugen to Participate in Upcoming July Industry Conferences
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Participate in Upcoming June Investor and Industry Conferences
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
    From Ocugen
    Via GlobeNewswire
    News headline image
    3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
    Via The Motley Fool
    News headline image
    Ocugen to Participate in Upcoming May Scientific and Investor Conferences
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen Provides Business Update with First Quarter 2026 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
    From Ocugen
    Via GlobeNewswire
    Top movers in Monday's after hours session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Ocugen, Inc. - Common Stock publicly traded?
    Yes, Ocugen, Inc. - Common Stock is publicly traded.
    What exchange does Ocugen, Inc. - Common Stock trade on?
    Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ocugen, Inc. - Common Stock?
    The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
    What is the current price of Ocugen, Inc. - Common Stock?
    The current price of Ocugen, Inc. - Common Stock is 1.045
    When was Ocugen, Inc. - Common Stock last traded?
    The last trade of Ocugen, Inc. - Common Stock was at 10/01/26 01:32 PM ET
    What is the market capitalization of Ocugen, Inc. - Common Stock?
    The market capitalization of Ocugen, Inc. - Common Stock is 268.91M
    How many shares of Ocugen, Inc. - Common Stock are outstanding?
    Ocugen, Inc. - Common Stock has 269M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.